Jasper Therapeutics, Inc.

JSPRW

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Rock Springs Capital

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Rock Springs CapitalNEWFeb 17, 2026

Shares: 1,100,726Value: $2.0M

# Signal Note: Rock Springs Capital Initiates Jasper Therapeutics Rock Springs' $2M entry into JSPRW (pre-revenue stage) signals conviction in Jasper's HSC435 program, a CD34+ hematopoietic stem cell therapy targeting severe aplastic anemia and other blood disorders. The position timing likely anticipates near-term clinical readouts; HSC435 entered Phase 2 for SAA in 2023, with data expected in 2024-2025. This is a high-risk/high-conviction bet by a concentrated healthcare specialist with selective initiation history.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

MLYS1 fund NBIX1 fund OLMA1 fund MIRM1 fund AMLX1 fund NAMSW1 fund OMDA1 fund REGN

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: